Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.58 |
| ▸ | FAP | Q12884 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30574548 | 0.94 | DPP4 (0.53) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL26210944 | 0.88 | ALDH1A1 (0.47) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL6779815 | 0.86 | DPP4 (0.63) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL28202772 | 0.85 | DPP4 (0.62) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12658450 | 0.85 | DPP4 (0.62) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL28202773 | 0.85 | DPP4 (0.62) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL6341798 | 0.85 | DPP4 (0.49) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL25383266 | 0.84 | DPP4 (0.53) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL30661440 | 0.83 | DPP4 (0.68) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL22901867 | 0.83 | DPP4 (0.51) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | DPP4 570/4885DPP7 369/4885DPP8 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.